Brii Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by the board of directors (the "**Board**") of Brii Biosciences Limited (the "**Company**") on a voluntary basis.

The Board is pleased to announce that, the Company received the topline data readout from full patient population from the phase 3 analysis of the National Institutes of Health ("**NIH**")-sponsored ACTIV-2 trial, which is developed by Accelerating COVID-19 Therapeutic Interventions Vaccines program clinical trial ("**ACTIV**"), evaluating the Company's investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, the amubarvimab/romlusevimab combination (previously BRII-196/BRII-198 combination).

All participants through the 28-day primary endpoint and the topline data readout remains consistent with the results and conclusions identified as part of the interim analysis as set out in the announcement of the Company dated August 25, 2021, demonstrating a statistically significant reduction, 80%, of relative risk in the combined endpoint of hospitalization and death in non-hospitalized COVID-19 patients at high risk of clinical progression. The analysis also showed zero deaths in the treatment arm versus nine deaths in the placebo arm through 28 days. Grade 3 or higher adverse events were less common in the amubarvimab/romlusevimab combination treatment arm versus in the placebo, with no drug related severe adverse events or infusion reactions observed.

The previous interim results announced by the Company on August 25, 2021, demonstrated that the combination therapy achieved a statistically significant reduction, 78%, of relative risk in the combined endpoint of hospitalization and death in non-hospitalized COVID-19 patients at high risk of clinical progression (nominal one-sided p value = 0.00001).

Current in vitro pseudo-virus testing data suggests that the amubarvimab/romlusevimab combination retains activity against major SARS-CoV-2 variants of concern, including the following commonly identified variants, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.617.2 (Delta), AY.4.2 (Delta Plus), C.37 (Lambda), and B.1.621 (Mu). Testing against the recent B.1.1.529 (Omicron) variant is currently ongoing. Data on the clinical efficacy of the amubarvimab/romlusevimab combination by variant type will also be evaluated as part of the ACTIV-2 study.

Cautionary Statement: There is no assurance that the amubarvimab and romlusevimab will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, December 5, 2021

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.